Collegium Pharmaceutical, Inc. (COLL)
| Market Cap | 1.32B |
| Revenue (ttm) | 780.57M |
| Net Income (ttm) | 62.87M |
| Shares Out | 31.75M |
| EPS (ttm) | 1.73 |
| PE Ratio | 24.02 |
| Forward PE | 5.10 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 892,324 |
| Open | 43.50 |
| Previous Close | 44.22 |
| Day's Range | 40.76 - 44.06 |
| 52-Week Range | 23.23 - 50.79 |
| Beta | 0.65 |
| Analysts | Strong Buy |
| Price Target | 50.83 (+21.98%) |
| Earnings Date | Feb 26, 2026 |
About COLL
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxyco... [Read more]
Financial Performance
In 2025, Collegium Pharmaceutical's revenue was $780.57 million, an increase of 23.62% compared to the previous year's $631.45 million. Earnings were $62.87 million, a decrease of -9.13%.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for COLL stock is "Strong Buy." The 12-month stock price target is $50.83, which is an increase of 21.98% from the latest price.
News
Collegium Pharmaceutical, Inc. (COLL) Q4 2025 Earnings Call Transcript
Collegium Pharmaceutical, Inc. (COLL) Q4 2025 Earnings Call Transcript
Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results
– Generated Quarterly Net Revenues of $205.4 Million, Up 13% Year-over-Year, and Record Full-Year Net Revenues of $780.6 Million, Up 24% Year-over-Year –
Collegium Pharmaceutical: Buying The Projected Growth For 2026
Collegium Pharmaceutical demonstrates strong profitability, upgraded 2026 guidance, and a robust balance sheet, reinforcing my bullish outlook and conviction upgrade. COLL's growth is shifting from Xt...
Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference
STOUGHTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have four poster presentations highlighting real-world data from its ADHD prod...
Collegium Provides 2026 Financial Guidance and Business Update
– Product Revenues, Net Expected in the Range of $805 Million to $825 Million – – Jornay PM ® Net Revenue Expected in the Range of $190 Million to $200 Million – – Adjusted EBITDA* Expected in the Ran...
Collegium Announces the Closing of $980 Million Syndicated Credit Facility
STOUGHTON, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced the closing of its inaugural syndicated credit facility.
Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Jefferies ...
Collegium Pharmaceutical: Another Solid Quarter
Collegium Pharmaceutical, Inc. just delivered standout Q3 results, with EPS and revenue significantly surpassing expectations, driving a 15% stock surge. COLL focuses on pain management treatments and...
Collegium Pharmaceutical, Inc. (COLL) Q3 2025 Earnings Call Transcript
Collegium Pharmaceutical, Inc. ( COLL) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Ian Karp Vikram Karnani - CEO, President, Executive VP & Director Scott Dreyer - Executi...
Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance
– Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM ® Net Revenue of $41.8 Million; Grew Prescriptions by 20% Year-over-Year – – ...
Knight Therapeutics Announces Launch of JORNAY PM™ in Canada
MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of JORNAY PM™ (methylph...
Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025
STOUGHTON, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report third quarter 2025 financial results before the market opens on Th...
Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences
STOUGHTON, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have poster presentations highlighting real-world data from its differentiated...
Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing
STOUGHTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management team will ring the Nasdaq opening bell on October 14, 2025 at 9:30...
Collegium Pharmaceutical, Inc. (COLL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 2:35 PM EDT Company Participants Vikram Karnani - CEO, President, Executive VP &...
Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting
STOUGHTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present nine posters showcasing real-world data from its differentiated pain p...
Collegium Pharmaceutical, Inc. (COLL) Q2 2025 Earnings Call Transcript
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Colleen Tupper - Executive VP & CFO Ian Karp - Corporate Participant Scott...
Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook
– Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM ® Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-over-Year –...
Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025
STOUGHTON, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report second quarter 2025 financial results before the market opens on T...
Collegium Announces $150 Million Share Repurchase Program
STOUGHTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living wi...
Collegium Pharmaceutical: Stock Deserves A "Buy" Call On Undervaluation Of ADHD Drug
Collegium is shifting focus from opioids to ADHD with Jornay PM, which is showing strong prescription growth and could become a blockbuster product. The company is undervalued relative to peers, with ...
Collegium Announces $25 Million Accelerated Share Repurchase Program
STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living wit...
Collegium Pharmaceutical, Inc. (COLL) Q1 2025 Earnings Call Transcript
Call Start: 16:30 January 1, 0000 5:05 PM ET Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2025 Earnings Call May 8, 2025 16:30 ET Company Participants Ian Karp - Head, Investor Relations Vikram Ka...
Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
– Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM ® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM...
Collegium to Report First Quarter 2025 Financial Results on May 8, 2025
STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on T...